Ankylosing Spondylitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between the ages of 19 and 75 (over 19 and under 75) at the time of signing up for the study
- You have been diagnosed with rheumatoid arthritis (RA) or ankylosing spondylitis (AS) for at least 3 months before joining the study
- Your doctor has decided that you should be prescribed the medication "Adalloce" as part of your treatment
- You have never previously received the medication "Adalloce"
- You are willing to voluntarily sign a consent form after being fully informed about the study's purpose and details
Who may not be able to join:
- You have had an allergic reaction to Adalloce or any of its ingredients in the past
- You currently have active tuberculosis, a serious infection such as blood poisoning (sepsis), or certain types of rare infections (opportunistic infections)
- You have moderate to severe heart failure (confirm with trial site)
- Your doctor determines that Adalloce is not appropriate for you based on the approved guidelines for this medication
- The study doctor decides, for any reason, that it would not be suitable for you to take part
- You are currently taking part in another clinical drug trial, or you are already participating in a post-marketing study of Adalloce
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jeongyoon Choi, PI, Daegu Catholic University Medical Center
Phone: +82-2-828-0231
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Changes in quality of life (EQ-5D-5L) scores at 52 weeks from baseline in patients with RA and AS
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.